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Abstract
The endothelin axis, comprising endothelins (ET-1, ET-2 and ET-3) and their receptors (ETAR and ETBR), has emerged as
relevant player in tumor growth and metastasis. Here, we investigated the involvement of ET-1/ETAR axis in chronic
lymphocytic leukemia (CLL). CLL cells expressed higher levels of ET-1 and ETA receptor as compared to normal B cells. ET-1
peptide stimulated phosphoinositide-3-kinase and mitogen-activated protein kinase signaling pathways, improved survival
and promoted proliferation of leukemic cells throughout ETAR triggering. Moreover, the blockade of ETAR by the selective
antagonist BQ-123 inhibited the survival advantage acquired by CLL cells in contact with endothelial layers. We also found
that blocking ETAR via BQ-123 interferes with ERK phosphorylation and CLL pro-survival effect mediated by B-cell receptor
(BCR) activation. The pro-apoptotic effect of phosphoinositide-3-kinase d inhibitor idelalisib and mitogen-activated protein
kinase inhibitor PD98059 was decreased by the addition of ET-1 peptide. Then, ET-1 also reduced the cytotoxic effect of
fludarabine on CLL cells cultured alone or co-cultured on endothelial layers. ETAR blockade by BQ-123 inhibited the ET-1-
mediated protection against drug-induced apoptosis. Lastly, higher plasma levels of big ET-1 were detected in patients
(n = 151) with unfavourable prognostic factors and shorter time to first treatment. In conclusion, our data describe for the
first time a role of ET-1/ETAR signaling in CLL pathobiology. ET-1 mediates survival, drug-resistance, and growth signals in
CLL cells that can be blocked by ETAR inhibition.
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Introduction
Chronic lymphocytic leukemia (CLL) is the most common
leukemia in adults in the Western countries. CLL is caused by the
accumulation of a long-lived antigen-experienced B cell clone, of
which a small fraction is represented by actively proliferating cells
with approximately 1-2% of cells newly generated each day [1].
The small proportion of proliferating CLL cells is thought to
replenish leukemic population inside specific structures known as
proliferation centers, which are localized in lymph nodes and bone
marrow. Bidirectional interactions with surrounding non-trans-
formed cells of stromal and immune compartments inside
proliferation centers prolong CLL survival, mediate proliferation
stimuli, and protect cells from the effect of chemotherapeutics [2].
In addition, CLL activation inside tissue microenvironments may
induce genetic instability and contribute to progression towards a
more malignant phenotype through the acquisition of additional
genetic lesions [3].
The most promising novel therapeutic approaches emerging in
CLL clinical trials have been developed to target CLL microen-
vironment, by interfering with homing and migration of CLL cells
[4]. Indeed, recirculation of leukemic cells from peripheral blood
to protective niches has emerged as a relevant feature in the
progression of the disease, with the involvement of several
molecules such as chemokines, their receptors, adhesion molecules
and enzymes able to digest the extracellular matrix. Inside tissues,
CLL cells also experience a chronic antigen contact that implies
the engagement of the B cell receptor (BCR) signaling, leading to
activation of downstream pro-survival signaling molecules such as
nuclear factor-kB, Raf, mitogen-activated protein kinase MEK
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and extracellular signal regulated kinase (ERK) [4]. Moreover,
increasing evidence suggests that angiogenesis can play a role in
CLL patho-physiology [5]. CLL-infiltrated tissues are character-
ized by high vascularization levels with abnormal microvessels
mainly localized near proliferating CLL subclone [6]. Patients
with adverse clinical outcome show more vascularized CLL-
infiltrated tissues and increased angiogenesis-related factors in
plasma [7]. Furthermore, CLL contact with endothelial cells
mediates survival, proliferation and drug-resistance [6,8–10].
Among the most up-regulated genes activated in CLL cells after
contact with endothelial cells, we recently reported Endothelin-1
(ET-1) with a 9-fold increase [8].
ET-1 is a 21-aa peptide that mediates its action by activating
two G-protein-coupled receptor (GPCR) subtypes, ETA and ETB
receptors [11]. Major pathways and effectors downstream of ET
receptors include mitogen activated protein kinases (MAPKs) and
phosphatidylinositol 3- kinase (PI3K)/AKT signaling pathways,
adenylyl cyclase and phospholipases (PLCb and PLA2). Synthesis
of the biologically active ET-1 peptide is a multistep process. The
primary translation product of EDN1 gene is the 212-aa
preproET-1, which is cleaved by an endothelin converting enzyme
(ECE-1) to form the 38-aa big ET-1 and then to the biologically
active 21-aa ET-1 peptide [11]. In addition to its role as a potent
endogenous vasoconstrictor and mediator of cardiovascular and
renal disorders, the endothelin axis has emerged as relevant player
in tumor growth and metastasis by regulating cell survival,
angiogenesis, tumor-infiltrating immune cells, epithelial-to-mesen-
chymal transition, invasion and metastatic dissemination [12].
Endothelin receptor blockade represents the most promising
approach in controlling the pleiotropic activities of ET-1 [13].
We evaluated whether ET-1 signaling pathway may be involved
in CLL pathobiology. Our findings demonstrate a role of ET-1
signaling via ETAR in CLL prolonged survival, proliferation and
drug-resistance. The effects are mediated by the activation of
PI3K/AKT and ERK/MAPK signaling pathways. Interestingly,
the blockade of ETAR via BQ-123 interferes with the pro-survival
signal and ERK phosphorylation induced by BCR triggering. We
also demonstrated that ET-1 signaling attenuates the effect of
idelalisib, an inhibitor of PI3Kd and PD98059, a MEK inhibitor.
Moreover, ET-1/ETAR axis plays a role in CLL interaction with
endothelial cells, suggesting that ET-1 may contribute to establish
a nursing and protective niche in infiltrated tissues. A range of
specific and selective ETA antagonists have undergone preclinical
and clinical studies showing promising results in some cancer
settings mainly in combination with cytotoxic drugs. Collectively,
our findings suggest that ET-1/ETAR axis may represent a novel
therapeutic target in CLL.
Materials and Methods
Ethics statement
Written informed consent was obtained in accordance with the
Declaration of Helsinki with a protocol approved by the local
Institutional Review Board (Comitato Etico Provinciale di
Modena, protocol#1298-39/10).
CLL patients and samples
Blood samples were collected at diagnosis from 151 CLL
patients fulfilling standard clinical, morphological and immuno-
phenotypic criteria [14] at the Divisions of Hematology of Novara
(n = 73), Modena (n= 42), Siena (n= 26), and Rome (n = 10).
Plasma samples were obtained by blood centrifugation at
2000 rpm for 15 minutes, then centralized to the Hematology
Unit of Modena for big ET-1 quantification. Plasma samples from
the same patient at different time points during follow-up were also
evaluated in 8 CLL cases. Peripheral blood mononuclear cells
(PBMCs) collected from untreated CLL patients were isolated by
density gradient centrifugation (Ficoll, Pharmacia LKB Biotech-
nology, Piscataway, NY, USA) and cryopreserved in RPMI-1640
medium, 50% fetal bovine serum (FBS), and 10% DMSO and
stored in liquid nitrogen until use. Normal B lymphocytes were
also obtained from buffy coats of healthy donors (HD) from the
blood bank of Modena Hospital. To enrich for CLL and normal B
cells, PBMCs were incubated with CD19Microbeads (Miltenyi
Biotec, Auburn, CA, USA), obtaining a purity .99% as assessed
by flow cytometry using PE-conjugated CD19 Ab (Miltenyi
Biotec). All experiments were performed on highly purified CLL
and normal B cell samples.
Cell culture conditions
Purified CLL cells were suspended at a final concentration of
16106/ml in RPMI medium with 10% FBS and then plated in 24-
well plates. Human Umbilical Vein Endothelial Cells (HUVEC,
Cascade Biologics, Life Technologies, Carlsbad, CA, USA) were
cultured as previously described [8]. For co-culture experiments,
HUVEC cells were incubated until reaching 70% confluence and
CLL cells were then seeded onto HUVEC layer. Leukemic cells
were also stimulated with recombinant ET-1 peptide (Calbiochem,
Merck, Darmstadt, Germany) at 100 nM. To evaluate drug-
resistance, cells were exposed to fludarabine (2-Fluoroadenine 9-B-
D-arabinofuranoside, Sigma-Aldrich, St. Luis, MO, USA) at dose
of 1 mM, idelalisib (GS-1101) (Selleckchem, Houston, TX, USA)
at 0.5 mM, and PD98059 (Sigma-Aldrich) at 50 mM. When
indicated, CLL cells were pre-incubated with ETAR antagonist
BQ-123 (Sigma-Aldrich) for 20 minutes at 37uC (0.1 mM or 1 mM)
before EC co-culture or treatments with fludarabine or ET-1.
Recombinant human interleukin 2 (IL-2) (100 IU/mL) and CpG
oligonucleotides (1 mg/mL; ODN2006, InvivoGen, S.Diego, CA,
USA) were also used. To determine the effect of BQ-123 on CLL
survival mediated by BCR signaling, CLL cells (36106/mL) were
previously incubated at 37uC with or without 0.1 mM BQ-123 for
20 minutes, then stimulated with 10 mg/mL of anti-IgM (Sigma-
Aldrich) in complete RPMI medium. At the indicated time points,
CLL cells were collected by removal of the supernatant and then
being assayed. In co-culture experiments, the number of HUVEC
cells contaminating the supernatants derived from the spontaneous
detachment of apoptotic cells and increased during co-culture
time, reaching 0.6–0.9% after 7 days, as assessed by flow
cytometric stainings with APC-conjugated CD146 Ab (Miltenyi
Biotech) and Annexin V (eBioscience, San Diego, CA, USA). The
effect of HUVEC contamination in the analyzed samples was
excluded by different strategies, as indicated. Conditioned media
(CM) were also collected by centrifugation at 1600 rpm for 10
minutes and stored at 220uC before being assayed.
Flow cytometry
Cells were stained with rabbit polyclonal ETAR antibody
(Abgent, S.Diego, CA, USA) for 30 min in ice followed by FITC-
conjugated Goat anti-rabbit Ig for 30 min in ice (Becton
Dickinson, San Jose´, CA, USA) and APC-conjugated CD19
(Miltenyi Biotec) for 10 min at room temperature. Apoptotic cell
death of CLL cells was analyzed using Annexin V-FITC and
Propidium Iodide (PI) staining (eBioscience). HUVEC cells were
excluded by a lymphocyte gate set according to the different
relative size and granularity (forward scatter and side scatter).
Viability was defined as the percentage of Annexin V-/PI- cells
(lower left quadrant). Events were acquired using a FACSCalibur
cytometer (Becton Dickinson) and then analyzed by FlowJo
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Software (Tree Star, Ashland, OR). In addition, CFSE (5-[and 6]-
Carboxyfluorescein diacetate succinimidyl ester; eBioscience)
dilution assay was used to trace cell division by flow cytometry.
CD19+ CLL cells, stained with CFSE, were incubated or not with
BQ-123 (0.1 mM) and then plated onto the HUVEC layer. The
proliferative measure was evaluated after 4 days, gating the
CD19+ alive CLL cells and analyzed using FlowJo software. CLL
cell proliferation was also evaluated by cell cycle analysis. CD19+
CLL cells were treated or not with ET-1 (100 nM) overnight and
then incubated in citrate buffer containing 10 mg/ml PI (Sigma)
and 100 mg/ml RNase. Cell cycle profiles were analyzed using
Modfit LT software (Verity Software House, Topshem, ME,
USA). To exclude debris and aggregates, we gated live cells and
selected single cells according to FL2-A vs FL2-W plot. CLL cells
stimulated with rh-IL-2 and CpG oligonucleotides were used as
positive control in CFSE dilution assay and cell cycle analysis.
MTT assays
CLL activation was monitored using a yellow tetrazolium MTT
assay (Trevigen, Gaithersburg, MD, USA). In this assay,
dehydrogenases expressed by metabolically active cells convert
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-dyphenyl-tetrazolium bro-
mide) into intracellular purple formazan. CLL cells (100 mL/well)
were collected from cultures and then allowed to adhere into a 96-
well plate by centrifugation at 1000 rpm for 10 min. Cells were
then incubated with MTT at 37uC for 24 hours, followed by a
4 h-incubation with 100 mL detergent reagent. Absorbance
readings were performed at 570 nm in a microplate reader
(Infinite M200, Tecan, Ma¨nnedorf, Switzerland).
Enzyme-linked immunosorbent assays
Big ET-1 levels in conditioned media and plasma samples were
measured using Big Endothelin-1 (human) EIA kit (Enzo Life
Sciences, Farmingdale, NY, USA). The mean minimum detect-
able dose was 0.23 pg/mL. Each sample was tested in duplicate
and concentrations were reported in pg/mL.
Real-time PCR
RNA was extracted with the RNeasy Plus Mini kit (Qiagen,
Valencia, CA, USA). Then, RNA (100 ng) was reverse transcribed
using Transcription High fidelity cDNA Synthesis kit (Roche
Applied Science, Penzberg, Germany). ET-1 and ETAR mRNA
were amplified by using LightCycler 480 SYBR Green I Master
(Roche). Primers were as follows: ET-1, forward 59-
TCTCTGCTGTTTGTGGCTTG-39, reverse 59-GAGCT-
CAGCGCCTAAGACTG-39; ETAR, forward 59-TGGTGTG-
CACTGCGATCTTC-39, reverse 59-GCAATTCTCAAGCTG-
CCATTC-39; GAPDH, forward 59-GAAGGTGAAGGTCG-
GAGTC-39, reverse 59-GAAGATGGTGATGGGATTTC-39.
All samples were analyzed in real time on LightCycler 480 v.2
(Roche) in duplicate, as previously described [15].
Western blot
After 1 h starvation at 37uC in RPMI medium with 2% FBS,
freshly isolated CLL cells were cultured in suspension and
stimulated with 100 nM ET-1 peptide (Calbiochem, Merck) for
4 hours or 10 mg/mL anti-IgM for 10 minutes. When indicated,
CLL cells were pre-incubated with ETAR antagonist BQ-123
(Sigma) for 20 minutes at 37uC before stimulation. Cells were lysed
on ice for 10 minutes with lysis buffer supplemented with
dithiothreitol and protease inhibitor cocktail (BioVision, Milpitas,
CA, USA). Proteins (100 mg/lane) were electrophoresed on 4-20%
SDS-polyacrylamide gradient gels and transferred to nitrocellulose
membranes (Bio-Rad Laboratories, Hercules, CA, USA). Mem-
branes were immunoblotted with the following primary antibod-
ies: anti-ETAR rabbit Ab (1:1000; Abcam, Cambridge, MA, USA)
anti-Akt rabbit mAb (1:1000; Cell Signaling Tech, Beverly, MA,
USA) or anti-phospho-Akt rabbit mAb (Ser 473, 1:1000; Cell
Signaling Tech); anti-p44/42 MAPK (Erk1/2) rabbit mAb
(1:1000; Cell Signaling Tech) or anti-phospho-p44/42 MAPK
(Erk1/2) rabbit mAb (Thr202/Tyr204, 1:2000; Cell Signaling
Tech); anti-bactin mouse mAb (ab6276, 1:10000; Abcam). Then,
membranes were incubated with species-specific horseradish
peroxidase (HRP)-conjugated secondary antibody (1:50000; GE
Healthcare, Uppsala, Sweden). Blots were developed using
SuperSignal West Pico Chemiluminescent Substrate (Thermo
Scientific, Rockford, IL, USA). Images were acquired by
Chemidoc XRS+ and analyzed using Image Lab Software v.3.0
(Bio-Rad Laboratories).
Immunohistochemistry
Sections from lymph nodal biopsies and prostate cancer biopsies
were incubated with mouse monoclonal Anti-Endothelin1 anti-
body (Calbiochem, Merck, Darmstadt, Germany, dilution 1:250)
or with rabbit polyclonal ETAR antibody (Abgent, dilution 1:50).
Detection of bound antibody was performed with alkaline
phosphatase method using a streptavidin-biotin alkaline phospha-
tase complex kit (REAL Detection System, Dako, Glostrup,
Denmark). The alkaline phosphatase reaction was then developed
with Permanent Red (Dako) as chromogen.
Statistical analyses
Data were analyzed using SPSS version 20.0 (SPSS, Chicago,
IL, USA). The cut-off point for big ET-1 levels was selected
according to receiver operating characteristic (ROC) analysis using
treatment as state variable, and the Youden’s index was calculated
Figure 1. CLL cells express ET-1 and ETA receptor. (A) ET-1 and ETAR expression levels were evaluated by quantitative reverse-transcription PCR
on CLL cells (n = 10) and normal B lymphocytes (n = 6) purified from peripheral blood. Histograms depict mean6SEM of ET-1 and ETAR relative
expression. Results were normalized to the expression of GAPDH housekeeping gene. CLL cells show higher expression levels of both ET-1 and ETAR
mRNA compared to normal B cells (*p,0.05). (B) CLL cells or normal B lymphocytes purified from peripheral blood were allowed to adhere and then
stained with anti-ET-1 antibody. A representative case of 3 independent CLL samples and 3 normal B cell samples is shown. Original magnification,
400X for left panels, and 1000X for right panels. CLL cells show more intense stainings of ET-1 peptide than normal B cells. (C) Displayed are flow
cytometric histograms depicting the relative fluorescence intensity of 2 CLL samples and 2 normal B-cell samples stained with anti-CD19 and anti-
ETAR Abs. Mean fluorescence intensity ratio (MFIR) is displayed above the histograms and is calculated by dividing the mean fluorescence intensity
for ETAR by the mean fluorescence of the isotype control. Histograms on the right summarize MFIR data of B cells from 7 CLL patients and 6 normal
controls. Data are presented as mean6SEM. Increased expression of ETAR on the surface of CLL cells was measured as compared to normal B cells
(*p,0.05). (D) The immunoblots depict higher ETAR expression levels in CLL cells than in normal B lymphocytes purified from peripheral blood
detected by Western blot analysis. (E) Immunohistochemical evaluation of CLL-infiltrated lymph nodes (CLL LN) (n = 4) stained with antibodies against
ET-1 or ETA receptor showing positive CLL cells. A representative staining of lymph nodes from healthy donors (n = 3) is displayed, showing a faint ET-
1 expression on normal B lymphocytes identified by CD20 staining. Prostate cancer is shown as positive control. Original magnification, 200X in the
above panels and 400X in the bottom panels.
doi:10.1371/journal.pone.0098818.g001
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utilizing the sensitivity and specificity derived from ROC analysis.
Time to first treatment (TTFT) was estimated using product-limit
(Kaplan-Meier) method and the curves were compared between
groups using log-rank test. The 2-tailed unpaired or paired
Student t test (*p,0.05, **p,0.01, ***p,0.001) was used to
compare data between 2 experimental groups. Standard error of
the mean (SEM) is depicted as error bars.
Results
CLL cells express ET-1 and ETA receptor
CLL cells circulating in peripheral blood expressed ET-1 and
exposed ETAR on cell surface (Figure 1). Comparing the
expression levels between purified CLL cells (n = 10) and normal
B cells (n = 6) collected from peripheral blood, we found that ET-1
and ETAR were significantly over-expressed in CLL cells
(Figure 1A). Moreover, we stained CLL cells (n = 3) and normal
B cells (n = 3) with anti-ET-1 antibody, revealing an increased
amount of ET-1 peptide in CLL as compared to normal B
lymphocytes (Figure 1B). Then, we cultured purified CLL cells
(n = 13) and normal B cells (n = 4) for 72 hours and we quantified
the big ET-1 protein, 38-aa precursor of ET-1, in conditioned
media by ELISA. CLL secreted a mean level of ET-1 precursor of
4.061.1 pg/mL, ranging from 0.9 to 12.8 pg/mL. Conversely, we
did not detect ET-1 secretion by normal B cells (data not shown).
Interestingly, we observed that big ET-1 was mostly secreted by
leukemic cells derived from patients with unfavorable unmutated
IGHV genes (mean6SEM, 5.261.5 pg/mL) compared to mutat-
ed ones (1.260.14 pg/mL) (p= 0.027) (Figure S1 in File S1).
Furthermore, we quantified ETAR on the surface of CLL (n= 7)
and normal B lymphocytes (n = 6). CLL cells expressed ETAR at
higher levels (mean fluorescence intensity ratio, MFIR=3963) as
compared to normal B cells (MFIR=2763) (p = 0.017, Figure 1C).
No differential expression of ETAR was detected between mutated
and unmutated IGHV CLL subsets. In addition, CLL cells were
positive for ET-1 and ETAR when infiltrating lymph nodes. ET-1
staining was more intense in CLL cells localized inside prolifer-
ation centers. Prostate cancer was used as positive control
(Figure 1E).
Blocking ETAR reduces CLL survival and interferes with B
cell receptor (BCR) signaling
Serum-starved CLL cells (n = 6) were treated with 100 nM ET-
1 for 1 hour. Exposure to ET-1 was also performed after ETAR
blocking by pretreating cells with 0.1 mM BQ-123 for 20 minutes.
When CLL cells were stimulated with ET-1 peptide, we detected
the activation of PI3K/Akt and ERK/MAPK signaling pathways
through ETA receptor triggering (Figure 2A). To explore the role
of ET-1 in preserving CLL survival, leukemic cells (n = 6) were
cultured alone for 4 days in complete medium in presence of ET-1
peptide at 100 nM. CLL cell viability increased upon ET-1
stimulation, from 21%611% in untreated CLL to 35%612% in
ET-1 treated CLL cells (p = 0.0008, Figure 2B). Treatment with
BQ-123 at doses of 0.1 mM or 1 mM did not exert any cytotoxic
effect on CLL cells (n = 3) cultured alone from 24 to 96 hours (data
not shown). However, if stimulated with ET-1 peptide, the
blockade of ETAR by 0.1 mM and 1 mM BQ-123 abrogated the
ET-1-induced apoptosis resistance, decreasing CLL viability to
24%612% and 20%611% respectively (p = 0.003 and p=0.004,
Figure 2B and Figure S2 in File S1).
We previously demonstrated that CLL cells acquire a survival
advantage when cultured in direct contact with endothelial cells
[8]. Conditioned media collected after 72 h co-culture (n = 13)
were enriched of big ET-1 peptides secreted by both endothelial
and leukemic cells (mean6SEM, 487.6624.5 pg/mL). In addi-
tion, when co-cultured on endothelial layer, the expression of
ETAR was maintained at high levels by CLL cells (data not
shown), indicating that ET-1 signaling may be relevant in EC/
CLL interaction. Thus, we argued whether ET-1/ETAR axis
could be involved in survival advantage acquired by CLL when
cultured together with endothelial cells. CLL cells (n = 11),
pretreated or not with BQ-123 for 20 minutes, were cultured in
direct contact with endothelial layer (HC condition) for 96 hours.
We confirmed that CLL cells acquire a survival advantage when
co-cultured with endothelial cells, increasing the percentage of
viable cells from 24%66% in CLL alone to 39%66% in co-
culture (p = 0.0005). Blocking ETAR on CLL, by pretreating cells
with 0.1 mM and 1 mM BQ-123 before co-culture, abrogated the
pro-survival effect of endothelial cell contact, decreasing CLL
viability to 26%65% and 25%64% respectively (p = 0.0005 and
p= 0.0008, Figure 2C and Figure S2 in File S1). Interestingly,
CLL cells with mutated or unmutated IGHV genes showed similar
responsiveness to ETAR inhibitor treatment (Figure S3 in File S1).
Inhibition of ETAR induced apoptosis in CLL harboring 17p
deletion (n= 2), from 56% and 67% of viable cells in contact with
endothelial layer to 38% and 36% in the presence of BQ-123.
Activation of CLL cells via BCR sets in motion a cascade of
intracellular signaling events, including PI3K and MAPK path-
ways, that results in enhanced CLL survival. To determine the
effects of BQ-123 on CLL viability mediated via BCR, we
stimulated cells (n = 6) with anti-IgM in presence of 0.1 mM BQ-
123. As shown in Figure 2D, anti-IgM stimulation increased CLL
Figure 2. ET-1 mediates survival signal on CLL cells. (A) Serum-starved CLL cells were stimulated with 100 nM ET-1 for 1 hour, pretreating or
not cells with 0.1 mM BQ-123 (20 min). Western blot analysis of CLL cells was performed with anti-phospho-Akt, anti-Akt, anti-phospho-ERK, anti-ERK
and anti-b-actin antibodies. ET-1 stimulates Akt and ERK phosphorylation through ETAR. The immunoblots depict Akt and ERK activation in a
representative case. Histograms represent densitometric quantification (pAkt/total Akt ratio and pERK/total ERK ratio) of bands relative to phospho-
Akt, total Akt, phospho-ERK and total ERK normalized on b-actin. Data are presented as mean6SEM of 6 CLL patients relative to unstimulated control
(*p,0.05, ***p,0.001). (B) CLL cells (n = 6) were cultured with the addition of recombinant ET-1 peptide at 100 nM for 96 hours. CLL cell viability was
assessed by flow cytometry using Annexin V and PI staining. A lymphocyte gate was set according to the different relative size and granularity
(forward scatter and side scatter) and viable cells were defined as Annexin V-/PI-. Histograms represent mean6SEM at 96 h of 6 CLL patients
evaluated in 3 independent experiments. Two representative cases are depicted on the right, showing cell viability at 48 h, 72 h and 96 h. Control is
defined as viability of CLL cells cultured alone in complete medium. ET-1 stimulation improves CLL survival. The effect is inhibited by pre-treating CLL
cells with BQ-123 (0.1–1 mM) (**p,0.01, ***p,0.001). (C) CLL cells (n = 11), pretreated or not with BQ-123 (0.1–1 mM), were cultured on HUVEC cell
layer for 96 hours. CLL cell viability was assessed by flow cytometry, as described for panel B. Histograms represent data as mean6SEM of 11 CLL
patients evaluated in 4 independent experiments. Two representative cases are depicted on the right, showing cell viability at 48 h, 72 h and 96 h.
Control is defined as viability of CLL cells cultured alone in complete medium. Note that BQ-123 significantly reduces the CLL pro-survival effect
mediated by HUVEC contact (***p,0.001). (D) CLL cells were stimulated with 10 mg/mL of anti-IgM for 48 hours with or without 0.1 mM BQ-123. Dot
plots represent cell viability of 6 CLL patients evaluated in 3 independent experiments. The blockade of ETAR reduces the pro-survival effect of BCR
triggering in CLL cells (*p,0.05). (E) Serum-starved CLL cells were pretreated or not with 0.1 mM BQ-123 for 20 minutes before stimulation with anti-
IgM for 10 minutes. The immunoblots depict ERK phosphorylation in a representative case.
doi:10.1371/journal.pone.0098818.g002
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viability from 73%65% to 81%65% (p= 0.0006). Moreover, the
blockade of ETAR signaling by BQ-123 decreased the pro-survival
effect of BCR triggering to 7766% (p= 0.02). In addition, we
found that BQ-123 reduced ERK phosphorylation in response to
anti-IgM stimulation (Figure 2E).
ET-1 signaling mediates chemo-resistance through ETAR
Small molecules that target kinases downstream the BCR have
shown marked anti-tumor effects in clinical trials [16,17]. We
evaluated if the inhibition of CLL viability mediated in vitro by
molecules targeting effector proteins of BCR engagement may be
counteracted by ET-1 signaling. To this end, we treated CLL cells
with idelalisib at 0.5 mM or PD98059 at 50 mM with or without
100 nM ET-1 peptide. As shown in Figure 3, ET-1 signaling
attenuated the pro-apoptotic effect of both idelalisib and
PD98059. In particular, idelalisib decreased the CLL viability
from 7064% to 5765% (n= 8, p= 0.002). The stimulation with
ET-1 peptide reduced idelalisib effect (6264%, p= 0.004), that
was completely restored via ETAR inhibition (5565%, p= 0.02)
(Figure 3A). Likewise, the use of MEK inhibitor induced a
significant decrease of cell viability in 8 CLL patients from
7462% to 6462% (p= 0.003). ET-1 signaling counteracted the
effect of MEK inhibition, inducing an increase in CLL viability to
6962% (p= 0.001). CLL cells were resensitized to MEK
inhibition in the presence of BQ-123 (6463%, p= 0.006,
Figure 3B).
Lastly, we evaluated whether ET-1 could protect CLL cells
from fludarabine-induced apoptosis. Leukemic cells from an
independent subset of untreated CLL patients (n = 8) were also
cultured for 48 hours alone or in contact with endothelial layer
with the addition of fludarabine (1 mM) in presence or absence of
ET-1 peptide at 100 nM. In blocking experiments, CLL cells were
pre-incubated or not with BQ-123 for 20 minutes before
treatments. We found a significant inhibition of drug-induced
apoptosis in presence of ET-1 both in CLL cultured alone and in
CLL in co-culture on endothelial layer, with an increase in
viability from 25%67% and 28%66% in fludarabine-treated
CLL to 31%68% and 37%66% in CLL treated with fludarabine
and ET-1, respectively (p = 0.012 and p=0.003, Figure 3). Again,
treatment with BQ-123 was able to restore CLL sensitivity to
fludarabine-mediated apoptosis (p,0.01, Figure 3). Blocking
ETAR on CLL cells reversed the ET-1 mediated fludarabine-
resistance both in mutated and unmutated IGHV subsets and also
in 3 cases carrying unfavorable FISH aberrations (2 CLL with 11q
deletion and 1 trisomy 12) (data not shown).
ET-1 triggers CLL cell activation and proliferation
To explore the effect of ET-1 signaling pathway on CLL cell
activation, we stimulated serum-starved CLL cells (n = 7) with
100 nM ET-1 for 4 hours, then measuring the extent of
metabolically active cells able to release formazan in MTT assays.
As shown in Figure 4A, ET-1 stimulation determined a 1.3-fold
increase in CLL cell activation, that was neutralized by blocking
ETAR on leukemic cells (p,0.01 both). Moreover, CLL cells
(n = 15) were stimulated with ET-1 in combination with an agonist
specific for toll-like receptor 9 (TLR9) (CpG oligonucleotides) for 5
days. As shown in Figure 4B, CpG oligonucleotides determined a
2.9-fold increase in metabolically active CLL cells when added
alone and a 3.4-fold increase when used in combination with ET-1
(p,0.01 both, compared to cells cultured alone in medium). The
CLL activation was significantly inhibited by blocking ETAR
signaling. Furthermore, we established a direct contact between
CLL cells (n = 11), pretreated or not with BQ-123 0.1 mM, and
endothelial layer for 4 days and then we measured the activation
status of CLL cells. Endothelial cell-contact induced CLL cell
activation with a 3.2-fold increase as compared to cells cultured
alone (p,0.01). Floating HUVEC cells, derived from the
spontaneous cell detachment from the adherent monolayer, did
not show any formazan production, thus excluding that contam-
inating endothelial cells may determine the high levels of formazan
release in co-culture condition. We found that CLL activation due
to endothelial cell contact was significantly reduced by pretreating
CLL with BQ-123 (p,0.01) (Figure 4C).
We then investigated whether ET-1/ETAR signaling may
trigger CLL cell proliferation. As shown in Figure 4D, when CLL
cells (n = 8) were stimulated with 100 nM ET-1 overnight, we
detected a moderate but significant increase in the percentage of
CLL cells in S-phase as compared to the untreated control
(p = 0.0004). Furthermore, we cultured CFSE-stained CLL cells
(n = 9) in contact with endothelial layer for 4 days, then testing
proliferation by CFSE dilution assays on CD19+ alive CLL cells.
CLL cell stimulation with CpG oligonucleotides/IL-2 was used as
positive control (25% divided CLL cells). Contact with HUVEC
cells not only improved the percentage of viable cells but also
induced the division of 13.5%62.5% of CLL cells (p = 0.001).
Blocking ETAR on leukemic cells by BQ-123, cell proliferation
was significantly decreased to 11.6%62.5% (p= 0.002, Figure 4E
and 4F). Accordingly, the increased percentage of Ki67+ CLL cells
(from 1.3 to 5%) in contact with endothelial cells was reduced to
4.2% in presence of BQ-123 (n= 3, data not shown). Collectively,
these data demonstrate that activation of ET-1 pathway induces a
proliferative profile in CLL cells.
Big ET-1 plasma levels are predictor of short Time to First
Treatment (TTFT) in CLL
We measured the levels of ET-1 precursor (big ET-1 peptide) in
plasma samples collected at diagnosis from a multicentric cohort of
CLL patients (n = 151). Patients’ characteristics are summarized in
Table S1 in File S1. Big ET-1 levels ranged from 0.3 pg/mL to
28.9 pg/mL (median= 3.7 pg/mL). As shown in Figure 5, higher
Figure 3. ET-1 inhibits the pro-apoptotic effect of idelalisib, MEK inhibitor and fludarabine. CLL cells (n = 8) were treated with idelalisib at
0.5 mM (panel A) or PD98059, a MEK inhibitor, at 50 mM (panel B). When indicated, CLL cells were also incubated with BQ-123 at 0.1 mM before ET-1
stimulation. CLL cell viability was assessed by flow cytometry by using Annexin V and PI staining. CLL viable cells were defined as Annexin V-/PI-.
Histograms represent cell viability as mean6SEM at 48 hours of 8 CLL patients evaluated in 4 independent experiments. Control is defined as CLL
cells cultured without any treatment. Flow cytometric contour plots of one representative case are shown in panel C. The gates in the plots exemplify
viable CLL cells (Annexin V-/PI-, circled). ET-1 signaling reduces CLL sensitivity to both idelalisib and PD98059 (**p,0.001). BQ-123 restores the drug
effect on CLL cells (*p,0.01 for idelalisib, **p,0.001 for PD98059). In addition, CLL cells (n = 8) were cultured (panel D) alone in complete medium or
(panel E) in contact with HUVEC layer (HC). Fludarabine was added at 1 mM. Cells were also treated with 100 nM ET-1 and, as indicated, pretreated
with 0.1 mM BQ-123 (20 min). Histograms represent mean6SEM of the percentage of live cells at 48 h of 8 CLL patients evaluated in 4 independent
experiments. Control is defined as CLL cells cultured without any treatment alone in panel D and in co-culture in panel E. Flow cytometric contour
plots of one representative case are shown in panel F. The gates in the plots exemplify viable CLL cells (Annexin V-/PI-, circled). Of note, inhibition of
fludarabine-induced apoptosis is evident in presence of ET-1 both in CLL cultured alone and in CLL in co-culture. Again, treatment with BQ-123
improves CLL sensitivity to fludarabine-mediated apoptosis. (*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0098818.g003
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Figure 4. ET-1 induces CLL activation and proliferation through ETA receptor. Purified CLL cells, pretreated or not with 0.1 mM BQ-123,
were stimulated with 100 nM ET-1 for 4 hours (n = 7) in panel A, or with an agonist specific for toll-like receptor 9 (TLR9) (CpG oligonucleotides) and
IL-2 with/without ET-1 addition for 5 days (n = 15) in panel B, or with endothelial cell contact (HC) for 4 days (n = 11) in panel C. Histograms depict the
formazan release by metabolically active CLL cells as fold change compared to unstimulated control (untreated CLL cells cultured alone). Data are
presented as mean6SEM of 6 independent experiments. Of note, the CLL activation is significantly increased upon ET-1 stimulation and inhibited by
blocking ETAR signaling in all conditions. (D) After 1 h of serum-starvation, CLL cells (n = 8) were stimulated or not with ET-1 overnight. PI analysis was
performed to define cell cycle phases. Histograms represent the percentage of CLL cells in S-phase after treatment compared to unstimulated
control. (E) CFSE-labeled CLL cells were cultured for 4 days alone in complete medium (control) or on endothelial layers. Where indicated, CLL cells
were incubated for 20 min with 0.1 mM BQ-123 before co-culture. The proliferative measure was inspected for 4 days, gating the CD19+ live CLL cells.
The histograms represent cumulative data at 96 hours of 5 independent experiments by using 9 CLL patients. Data are shown as mean values6 SEM
of the percentage of dividing CLL cells. In panel F, the percentages of divided CLL cells at 48 h, 72 h and 96 h measured by CFSE dilution in a
representative CLL sample are shown. HUVEC cells stimulate CLL cells to divide. The addition of BQ-123 counteracts the EC-mediated proliferative
stimuli. (*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0098818.g004
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levels of big ET-1 were detected in patients with advanced Binet
stage (median, 3.5, 4.2 and 9.8 pg/mL in stage A, B and C
respectively, p = 0.004), unmutated IGHV status (median, 3.4 and
5.0 pg/mL in mutated and unmutated IGHV CLL subsets,
p = 0.003), intermediate/high FISH risk (median, 3.3 and 5.1 pg/
mL in low and high FISH risk subsets, p = 0.002). In particular, a
progressive increase in big ET-1 levels characterized CLL with
hierarchically ranked FISH abnormalities (3.2, 3.5, 4.3, 5.0 and
5.9 pg/mL in CLL with normal FISH, 13q deletion, trisomy 12,
11q and 17p deletions respectively) (Figure 5A). No differences in
big ET-1 levels were measured inside CD38 and ZAP-70 CLL
subsets. Notch1 mutation (c.7544_7545delCT p.P2515fs*4) was
detected in 9 patients, and TP53 mutations in 6 patients. Although
not reaching statistical significance, we found that increased levels
of big ET-1 were also present in patients harboring Notch1 and
TP53 mutations compared to other cases (median, 4.3 vs. 3.7 pg/
mL for Notch1; 5.5 pg/mL vs. 3.7 for TP53). A positive
correlation was detected between big ET-1 levels and lymphocyte
count (p,0.0001) or b2 microglobulin (p,0.0001) (Figure 5B).
Furthermore, we evaluated whether higher big ET-1 levels may
characterize CLL patients with adverse clinical outcome. We
found that patients with big ET-1 levels higher than a cutoff point
of 5.4 pg/mL (established by ROC analysis) showed shorter time
to first treatment (TTFT), as compared to CLL with low levels of
big ET-1 (median TTFT, 58 vs. 129 months, p= 0.005,
Figure 5C). Lastly, we performed a comparison of big ET-1 levels
between two sequential PB plasma samples collected from 8 CLL
cases with median interval of 5 years (range, 1–6 years). Four CLL
patients showed stable disease during follow up, whereas the
remaining cases were characterized by progressive disease. As
shown in Figure 5D, no difference in big ET-1 levels was found in
cases with stable disease during follow up. Conversely, increase in
big ET-1 plasma levels over time was measured in patients
experiencing disease progression (n= 4, 4.3 pg/mL at diagnosis
and 11.9 pg/mL pre-treatment).
Figure 5. High levels of big ET-1 are associated with worse clinical outcome in CLL patients. (A) Dot plots depict the levels of big ET-1 in
plasma samples collected at diagnosis from 151 CLL patients in relation to Binet stages, IGHV mutational status and FISH aberrations. Note that big
ET-1 levels increase in patients with advanced stages, unmutated IGHV genes and unfavorable FISH aberrations (p,0.05 in all instances). (B) Positive
correlation between big ET-1 levels and b2 microglobulin is represented (p,0.0001). (C) Kaplan-Meier curves for time to first treatment (TTFT).
Patients are stratified in high and low big ET-1 subsets based on a cut-off equal to 5.4 pg/mL. CLL patients with high levels of big ET-1 display
significantly shorter TTFT (p = 0.005; log-rank test). (D) Measurement of big ET-1 plasma levels in two plasma samples (diagnosis and follow up)
collected from 8 CLL cases. Dotted lines represent CLL patients with stable disease during follow up, whereas dashed lines depict CLL patients
showing progressive disease. Note that increase of big ET-1 plasma levels is measured in patients experiencing disease progression (n = 4, 4.3 pg/mL
at diagnosis and 11.9 pg/mL pre-treatment).
doi:10.1371/journal.pone.0098818.g005
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Discussion
ET-1 was discovered as a potent vasoconstrictor, but later it was
demonstrated to possess a wide range of pleiotropic functions,
including cell survival, proliferation, angiogenesis, and regulation
of tumor-infiltrating immune cells, invasion and metastasis
[12,18]. These actions are mediated through the ETA receptor,
whereas the triggering of ETB receptor counteracts these functions
in many cases [19,20].
ET-1 is synthetized and secreted by human endothelial cells,
many epithelial cell types, peripheral blood monocytes, differen-
tiated macrophages, and mature dendritic cells [18,20,21]. ET-1 is
also reported to be expressed by several tumor cell lines and
primary solid neoplasia [22,23]. In contrast, endothelin-1 is
undetectable in unstimulated B and T lymphocytes or neutrophils
and in several cell lines from hematological malignancies
[21,22,24,25]. We demonstrated for the first time that CLL cells
circulating in peripheral blood and infiltrating lymph nodal
compartments synthetize ET-1 peptide and express ETA receptor
on cellular surface. Leukemic cells expressed higher levels of ET-1
than normal B cells both in the peripheral blood and in lymph
nodes. Again, CLL cells showed increased amount of ETAR as
compared to circulating B cells from healthy donors. The
difference seems particularly impressive at transcriptional levels
and when total ETAR protein expression was detected by western
blot, but to a lesser extent when measured on the cell surface. One
possible explanation would be that ET-1 binding to ETAR on
CLL cells promotes receptor internalization. Upon ET-1 binding,
ET receptors have been shown to form homodimers and
heterodimers, and to accumulate in the cell interior, then
subsequently become sorted to distinct cellular fates. ETA is
typically recycled back to the plasma membrane in an un-liganded
state, whereas ETBR is targeted to lysosomes for degradation [26].
Further studies will be necessary to elucidate these mechanisms
that can have profound effects on ligand binding, receptor
activation, desensitization, and membrane trafficking in CLL
cells. ET-1 peptide, measured as the 38-aa precursor big ET-1,
was detected in conditioned media collected from CLL cells, and
also accumulated at high levels when leukemic cells were cultured
in direct contact with endothelial cells. Conversely, normal B cells
did not secrete ET-1 in vitro. Overall, our findings suggested that
endothelin-1 signaling may be abnormally activated in leukemic
cells compared to normal B cells.
ET-1 is a known survival factor for many normal and tumoral
cell types, acting mainly through ETA receptor [12,18,27]. We
argued whether ET-1 signaling pathway may trigger survival
stimuli on CLL cells by establishing an autocrine loop and/or by
acting throughout microenvironment. We observed an enhanced
resistance to spontaneous apoptosis in CLL cells cultured with
recombinant ET-1. The effect was reversed by blocking ETA
receptor with the selective antagonist BQ-123, meaning that ET-
1-mediated ETAR activation triggers protective and antiapoptotic
signals on CLL cells. Accordingly, we demonstrated that ET-1
activates PI3 kinase and MAP kinase signaling pathways in CLL
cells throughout ETAR triggering. Signals from the tumor
microenvironment play a pivotal role in the maintenance and
survival of CLL cells. In particular, BCR signaling has been
recognized as an essential signal for CLL selection and expansion
[28–31]. Engagement of BCR mediates Btk phosphorylation,
which in turn activates several downstream signaling molecules
such as PI3K and MEK protein kinases. Inhibitors of kinases
involved in BCR signal transduction have demonstrated substan-
tial clinical activity in CLL [16,17]. The fact that ET-1 and BCR
signals converge to common downstream pathways may be of
interest. Here, we found that blocking ETAR via BQ-123
interferes with ERK phosphorylation and CLL pro-survival effect
mediated by BCR activation.
We and others recently demonstrated that the contact with
endothelial cells rescues CLL from spontaneous and drug-induced
apoptosis, induces activation and proliferation and generates a
peculiar gene expression profile on leukemic cells [6,8,10,32]. ET-
1 was observed among the most up-regulated genes in CLL after
co-culture and is also secreted at high amount by activated
endothelium. In addition, interaction with endothelial cells
improved CLL survival by physical contact throughout b1- and
b2- integrins but also by secretion of soluble factors [8]. As
consequence, we argued whether ET-1 may be involved in CLL/
endothelial cell crosstalk. We demonstrated that the blockade of
ETAR on CLL cells significantly reduces apoptosis-resistance
acquired by CLL cells after contact with endothelial layer.
We also evaluated whether ET-1 signaling may determine
protection against drug-induced apoptosis as reported in solid
tumors [33–35]. We found that ET-1 reduces the cytotoxic effect
of fludarabine on CLL cells cultured alone in complete media or
co-cultured on endothelial layers. ETAR blockade by BQ-123
antagonist inhibited the ET-1-mediated protection against fludar-
abine-induced apoptosis. Given the interconnected signaling
network of ET-1, it is also important to explore the potential
value of combinatorial therapies with signal transduction inhibi-
tors such as lipid kinase PI3Kd inhibitor idelalisib and MEK
inhibitor PD98059. Here, we found that ET-1 signaling decreased
the pro-apoptotic effect of both molecules. The combination with
BQ-123 completely neutralized the protective effect of ET-1.
Remarkably, despite the CLL heterogeneous sensitivity to MEK
inhibition [36], the blockade of ETAR restored the CLL sensitivity
to PD98059 in all CLL cases. In this scenario, the ET-1 peptide
secreted by CLL cells or by other cell types, such as endothelial
cells inside infiltrated tissues, could interfere with the effect of
novel molecules currently undergoing clinical trial with promising
results [16,37].
It has been reported that ET-1 stimulates mitogenic responses
and expression of proto-oncogenes in normal cell types (vascular
smooth muscle cells, fibroblast, and glomerular mesangial cells)
and also in several human cancer cell lines and primary tumor
cells [38–41]. We demonstrated that ETAR triggering mediates
proliferative stimuli on CLL cells, including activation of MAP
kinase signaling pathway, cell cycle progression and increased
number of divided cells. The blockade of ETA receptor on CLL
cells by BQ-123 reduced the extent of proliferating subclone that
resulted by intimate contact with endothelial cells. These findings
support the view that ET-1 could participate in the maintenance
and progression of leukemic clone inside tissues. Although the
majority of circulating CLL cells are quiescent, a small prolifer-
ative compartment does exist in CLL conceivably within the
lymph nodes and bone marrow, where leukemic cells may take
advantage of interactions with the microenvironment [1,42].
Intimate contact with surrounding non-transformed cells, extra-
cellular matrix elements and soluble factors affect CLL-cell
survival and proliferation, induce genetic instability and contribute
to clonal evolution [2,30]. In this scenario, ET-1/ETAR axis may
be a relevant player in maintaining CLL clone by inducing
apoptosis resistance and protection against drug effects, and also
by providing growth and proliferative stimuli inside microenvi-
ronmental tissues.
Elevated plasma levels of ET-1 were detected in patients
diagnosed with various solid tumors and may be useful in
predicting survival [43–48]. Due to low circulating concentration
and short plasma half-life (,1.5 minutes), measurement of ET-1
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21-residue peptide in plasma has proven to be difficult. Big ET-1 is
a stable peptide with a half-life of 30 minutes in plasma and may
represent a sensitive and valuable indicator of endothelin system
activation [49]. We measured the levels of big ET-1 in plasma
samples collected at diagnosis from a multicentric cohort of
151 CLL patients. Increased levels of big ET-1 characterized
patients with advanced clinical stages, unmutated IGHV genes,
higher lymphocyte count and b2 microglobulin levels. Moreover,
a progressive increase in big ET-1 levels was detected in CLL
harboring high risk FISH abnormalities, i.e. 17p and 11q
deletions. Noteworthy, patients with higher levels of big ET-1 in
plasma showed shorter time to first treatment. In agreement,
patients with stable disease did not experience any increase in big
ET-1 overtime, whereas higher amount of big ET-1 compared to
diagnosis could be measured in patients with disease progression.
The results support the notion that the activation status of
endothelin system may be of relevance in CLL clinical outcome.
Several issues concerning the role of endothelin system in CLL
remain to be explored. First, multiple mechanisms both at
transcriptional and post-translational levels may be implicated in
the abnormal levels of ET-1 and ETAR on CLL cells as compared
to normal B cells. Second, the mechanisms underlying ET-1-
induced mitogenesis involve the activation of several pathways,
including the production of second messengers, calcium release,
and synergism with growth factors such as interleukin-6, basic
fibroblast growth factor and vascular growth factor. Furthermore,
there is experimental evidence from other cellular systems, mainly
smooth muscle cells, that the ET-1/ETAR axis is functionally
associated to CD38 and the localization in well-defined area of the
cell membrane is critical for the activation of CD38 and ET-1/
ETAR pathways [50–52]. Interestingly, CLL cells also expressed
ETBR on the cell surface (data not shown), even if at lower levels
as compared to ETAR. Generally, ETB receptor activation
operates in a counter-regulatory fashion to ETAR and leads to
cell apoptosis, but in some cell types ETBR was reported to
mediate cell survival. Here, we deeply investigated the pleiotropic
actions of ETA receptor triggering in CLL cells. Further studies are
needed to clarify the role of ETB receptor. In view of the promising
activity of the dual ETAR and ETBR antagonists in preclinical
models of ovarian cancer, and the well-tolerated toxicity profile
[53,54], these molecules might be explored in CLL in combination
with chemotherapy and kinase inhibitors. In conclusion, our data
show for the first time that CLL cells produce ET-1 and express
ET receptors at higher levels compared to normal B lymphocytes.
The results also demonstrate that ET-1/ETAR axis plays a role in
survival, drug-resistance and proliferation of leukemic cells. The
observed ability of ETAR selective antagonist to interfere with
intrinsic and extrinsic growth/protective signals of CLL cells may
be explored, both experimentally and clinically, as a possible novel
therapeutic approach in CLL.
Supporting Information
File S1 Contains the files: Figure S1. ET-1 expression in
mutated vs. unmutated IGHV CLL subsets. (A) ET-1
expression levels were evaluated by quantitative reverse-transcrip-
tion PCR on mutated IGHV CLL (n= 3) and unmutated IGHV
CLL (n= 7) cells purified from peripheral blood. Histograms
depict mean6SEM of ET-1 relative expression. Results were
normalized to the expression of GAPDH housekeeping gene. No
differential expression of ET-1 mRNA is evident between the two
subsets. (B) Big ET-1, the 38-aa precursor of ET-1, was quantified
by ELISA in conditioned media obtained after 72 h-culture from
4 mutated IGHV CLL and 9 unmutated ones. Histograms depict
mean6SEM of big-ET-1 levels in pg/mL. Unmutated CLL cells
secrete higher levels of big-ET-1 as compared to mutated CLL
(*p,0.05). Figure S2. ET-1 signaling improves CLL
survival and promotes fludarabine resistance. (A) CLL
cells (n = 6), pre-treated or not with 0.1 mM or 1 mM BQ-123,
were stimulated with 100 nM ET-1. Viability was inspected by
flow cytometry using Annexin-PI staining. Histograms represent
mean6SEM of the percentage of viable cells (Annexin V-/PI-) in
3 independent time course experiments from 48 h to 96 h. ET-1
stimulation improves CLL viability at 96 h when leukemic cells
decrease their spontaneous apoptosis resistance in vitro. (B) CLL
cells (n = 11), pre-treated or not with 0.1 mM or 1 mM BQ-123,
were cultured in contact with endothelial layers. Viability was
inspected by flow cytometry using Annexin-PI staining. Histo-
grams represent mean6SEM of the percentage of viable cells
(Annexin V-/PI-) in 4 independent time course experiments from
48 h to 96 h. The blockade of ETAR by BQ-123 affects EC-
mediated survival advantage at 72 h and 96 h. CLL cells (n = 8)
were cultured (panel C) alone in complete medium or (panel D) in
contact with HUVEC layer (HC). Fludarabine was added at
1 mM. Cells were also treated with 100 nM ET-1 and, as
indicated, pretreated with 0.1 mM BQ-123 (20 min). Histograms
summarize data at 24 h and 48 h, showing ET-1 mediated
fludarabine-resistance at 48 hours. Control is defined as viability
of CLL cells cultured alone in complete medium in panels A, B
and C or in co-culture in panel D. (*p,0.05). Figure S3. The
blockade of ETAR by BQ-123 induces apoptosis on both
mutated IGHV and unmutated IGHV CLL subsets. (A)
CLL cells (n = 6, 3 mutated IGHV and 3 unmutated IGHV CLL),
pre-treated or not with 0.1 mM or 1 mM BQ-123, were stimulated
with 100 nM ET-1. (B) CLL cells (n = 11, 4 mutated IGHV and 7
unmutated IGHV CLL), pre-treated or not with 0.1 mM or 1 mM
BQ-123, were cultured in contact with endothelial layers. Viability
was inspected by flow cytometry using Annexin-PI staining.
Histograms represent mean6SEM of the percentage of viable cells
(Annexin V-/PI-) at 96 h of CLL divided into mutated vs.
unmutated IGHV subsets. Control is defined as viability of CLL
cells cultured alone in complete medium. (*p,0.05, **p,0.01).
Table S1. Patients’ characteristics (n = 151).
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